Cite
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
MLA
Dufour, Christelle, et al. “Prognostic Relevance of Clinical and Molecular Risk Factors in Children with High-Risk Medulloblastoma Treated in the Phase II Trial PNET HR+5.” Neuro-Oncology, vol. 23, no. 7, July 2021, pp. 1163–72. EBSCOhost, https://doi.org/10.1093/neuonc/noaa301.
APA
Dufour, C., Foulon, S., Geoffray, A., Masliah-Planchon, J., Figarella-Branger, D., Bernier-Chastagner, V., Padovani, L., Guerrini-Rousseau, L., Faure-Conter, C., Icher, C., Bertozzi, A.-I., Leblond, P., Akbaraly, T., Bourdeaut, F., André, N., Chappé, C., Schneider, P., Carli, E. D., Chastagner, P., & Berger, C. (2021). Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro-Oncology, 23(7), 1163–1172. https://doi.org/10.1093/neuonc/noaa301
Chicago
Dufour, Christelle, Stephanie Foulon, Anne Geoffray, Julien Masliah-Planchon, Dominique Figarella-Branger, Valerie Bernier-Chastagner, Laetitia Padovani, et al. 2021. “Prognostic Relevance of Clinical and Molecular Risk Factors in Children with High-Risk Medulloblastoma Treated in the Phase II Trial PNET HR+5.” Neuro-Oncology 23 (7): 1163–72. doi:10.1093/neuonc/noaa301.